Why Reviewing MDR Grace Period Interpretation Is Only Way To Stop Threat To Device Availability
Something must be done to allow more products to be reviewed under the existing medical device directives by 26 May
Executive Summary
With just under 120 days until the full application of the EU’s Medical Device Regulation, and fears growing of the loss of products seen as non-compliant, the EU medtech industry has identified a way of broadening the application of the “grace period.” It is a legal way of addressing the potential loss of tens of thousands of products come 26 May, says MedTech Europe’s Oliver Bisazza.
You may also be interested in...
Industry And Notified Bodies Get Last Chance To Sway Authorities At Key EU MDR Meeting
It looks like it's the last chance saloon for industry to argue for vital concessions over the implementation of the EU Medical Device Regulation – at the final meeting of the European Commission’s MDCG implementation support group before the regulation fully applies.
EU Regulatory Experts Support Notified Bodies, But Argue For Greater Consistency
Notified bodies have been a pivotal part of the EU medtech regulatory system since it was first launched in the 1990s. Where might they fit within a new medtech regulatory governance structure? Panelists on a recent vodcast grappled with the question.
First Public Discussion On How EU Medtech Regulatory Governance Structure May Evolve
Does the EU need a medtech agency for the first time in its history? Nothing can or should be decided too quickly but five high-profile experts broadly agreed that change is now critical.